S&P 500   3,930.71 (-1.70%)
DOW   33,504.54 (-1.30%)
QQQ   282.02 (-1.95%)
AAPL   143.94 (-1.83%)
MSFT   245.05 (-2.06%)
META   114.99 (-6.08%)
GOOGL   97.49 (-2.00%)
AMZN   88.60 (-2.65%)
TSLA   177.71 (-2.60%)
NVDA   160.54 (-3.35%)
NIO   13.01 (+1.64%)
BABA   91.32 (+0.88%)
AMD   70.90 (-3.69%)
T   19.00 (+1.33%)
MU   53.75 (-0.54%)
CGC   3.62 (-16.20%)
F   13.10 (-2.09%)
GE   85.02 (+0.43%)
DIS   93.04 (-3.01%)
AMC   6.74 (-9.53%)
PYPL   72.08 (-2.09%)
PFE   49.36 (-2.70%)
NFLX   305.77 (-2.18%)
S&P 500   3,930.71 (-1.70%)
DOW   33,504.54 (-1.30%)
QQQ   282.02 (-1.95%)
AAPL   143.94 (-1.83%)
MSFT   245.05 (-2.06%)
META   114.99 (-6.08%)
GOOGL   97.49 (-2.00%)
AMZN   88.60 (-2.65%)
TSLA   177.71 (-2.60%)
NVDA   160.54 (-3.35%)
NIO   13.01 (+1.64%)
BABA   91.32 (+0.88%)
AMD   70.90 (-3.69%)
T   19.00 (+1.33%)
MU   53.75 (-0.54%)
CGC   3.62 (-16.20%)
F   13.10 (-2.09%)
GE   85.02 (+0.43%)
DIS   93.04 (-3.01%)
AMC   6.74 (-9.53%)
PYPL   72.08 (-2.09%)
PFE   49.36 (-2.70%)
NFLX   305.77 (-2.18%)
S&P 500   3,930.71 (-1.70%)
DOW   33,504.54 (-1.30%)
QQQ   282.02 (-1.95%)
AAPL   143.94 (-1.83%)
MSFT   245.05 (-2.06%)
META   114.99 (-6.08%)
GOOGL   97.49 (-2.00%)
AMZN   88.60 (-2.65%)
TSLA   177.71 (-2.60%)
NVDA   160.54 (-3.35%)
NIO   13.01 (+1.64%)
BABA   91.32 (+0.88%)
AMD   70.90 (-3.69%)
T   19.00 (+1.33%)
MU   53.75 (-0.54%)
CGC   3.62 (-16.20%)
F   13.10 (-2.09%)
GE   85.02 (+0.43%)
DIS   93.04 (-3.01%)
AMC   6.74 (-9.53%)
PYPL   72.08 (-2.09%)
PFE   49.36 (-2.70%)
NFLX   305.77 (-2.18%)
S&P 500   3,930.71 (-1.70%)
DOW   33,504.54 (-1.30%)
QQQ   282.02 (-1.95%)
AAPL   143.94 (-1.83%)
MSFT   245.05 (-2.06%)
META   114.99 (-6.08%)
GOOGL   97.49 (-2.00%)
AMZN   88.60 (-2.65%)
TSLA   177.71 (-2.60%)
NVDA   160.54 (-3.35%)
NIO   13.01 (+1.64%)
BABA   91.32 (+0.88%)
AMD   70.90 (-3.69%)
T   19.00 (+1.33%)
MU   53.75 (-0.54%)
CGC   3.62 (-16.20%)
F   13.10 (-2.09%)
GE   85.02 (+0.43%)
DIS   93.04 (-3.01%)
AMC   6.74 (-9.53%)
PYPL   72.08 (-2.09%)
PFE   49.36 (-2.70%)
NFLX   305.77 (-2.18%)
NASDAQ:ITRM

Iterum Therapeutics - ITRM Stock Forecast, Price & News

$1.31
-0.01 (-0.76%)
(As of 12/6/2022 01:07 PM ET)
Add
Compare
Today's Range
$1.31
$1.31
50-Day Range
$1.25
$1.98
52-Week Range
$1.21
$7.49
Volume
100 shs
Average Volume
39,778 shs
Market Capitalization
$16.02 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Iterum Therapeutics MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
1.83% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Selling Shares
$160,442 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($3.20) to ($5.55) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.22 out of 5 stars

Medical Sector

997th out of 1,023 stocks

Pharmaceutical Preparations Industry

487th out of 501 stocks

ITRM stock logo

About Iterum Therapeutics (NASDAQ:ITRM) Stock

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.

Receive ITRM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Iterum Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ITRM Stock News Headlines

H.C. Wainwright Keeps Their Hold Rating on Iterum Therapeutics (ITRM)
Iterum Therapeutics to Present Data at IDWeek 2022
Iterum Therapeutics Shares Are Surging - Read Why
Iterum Therapeutics plc Ordinary Share (ITRM)
See More Headlines
Receive ITRM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Iterum Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ITRM Company Calendar

Last Earnings
11/10/2022
Today
12/06/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/27/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ITRM
Fax
N/A
Employees
13
Year Founded
N/A

Profitability

Net Income
$-91,560,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$40,000.00
Book Value
$4.12 per share

Miscellaneous

Free Float
11,793,000
Market Cap
$16.02 million
Optionable
Not Optionable
Beta
1.32

Key Executives

  • Mr. Corey N. Fishman (Age 57)
    Pres, CEO & Director
    Comp: $939.26k
  • Ms. Judith M. Matthews (Age 52)
    Chief Financial Officer
    Comp: $533.85k
  • Dr. Michael W. Dunne M.D. (Age 62)
    Strategic Advisor & Director
    Comp: $377.8k
  • Dr. Sailaja Puttagunta M.D. (Age 53)
    Chief Medical Officer
    Comp: $125.79k
  • Mr. Tom Loughman Ph.D.
    Sr. VP of Technical Operations
  • Ms. Louise Barrett
    Sr. VP of Legal Affairs & Sec.
  • Dr. Steven I. Aronin M.D.
    Sr. VP & Head of Clinical Devel.













ITRM Stock - Frequently Asked Questions

Should I buy or sell Iterum Therapeutics stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Iterum Therapeutics in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ITRM shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ITRM, but not buy additional shares or sell existing shares.
View ITRM analyst ratings
or view top-rated stocks.

How have ITRM shares performed in 2022?

Iterum Therapeutics' stock was trading at $5.88 at the beginning of the year. Since then, ITRM shares have decreased by 77.7% and is now trading at $1.31.
View the best growth stocks for 2022 here
.

Are investors shorting Iterum Therapeutics?

Iterum Therapeutics saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 217,400 shares, an increase of 85.0% from the October 31st total of 117,500 shares. Based on an average daily volume of 70,400 shares, the days-to-cover ratio is presently 3.1 days. Currently, 1.8% of the company's shares are sold short.
View Iterum Therapeutics' Short Interest
.

When is Iterum Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 27th 2023.
View our ITRM earnings forecast
.

How were Iterum Therapeutics' earnings last quarter?

Iterum Therapeutics plc (NASDAQ:ITRM) issued its quarterly earnings results on Thursday, November, 10th. The company reported ($0.43) earnings per share for the quarter, topping analysts' consensus estimates of ($0.92) by $0.49.

When did Iterum Therapeutics' stock split?

Shares of Iterum Therapeutics reverse split on Thursday, August 18th 2022. The 1-15 reverse split was announced on Thursday, August 18th 2022. The number of shares owned by shareholders was adjusted after the market closes on Thursday, August 18th 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What other stocks do shareholders of Iterum Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Iterum Therapeutics investors own include Aeglea BioTherapeutics (AGLE), Viking Therapeutics (VKTX), Acasti Pharma (ACST), Axsome Therapeutics (AXSM), Innovate Biopharmaceuticals (INNT), OPKO Health (OPK), VYNE Therapeutics (VYNE), Fulcrum Therapeutics (FULC), Ocugen (OCGN).

When did Iterum Therapeutics IPO?

(ITRM) raised $80 million in an IPO on Friday, May 25th 2018. The company issued 5,300,000 shares at a price of $14.00-$16.00 per share. Leerink Partners and RBC Capital Markets acted as the underwriters for the IPO and Guggenheim Securities and Needham & Company were co-managers.

What is Iterum Therapeutics' stock symbol?

Iterum Therapeutics trades on the NASDAQ under the ticker symbol "ITRM."

Who are Iterum Therapeutics' major shareholders?

Iterum Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include New Leaf Venture Partners L.L.C. (0.79%), Dimensional Fund Advisors LP (0.51%), Renaissance Technologies LLC (0.28%) and Krilogy Financial LLC (0.16%). Insiders that own company stock include Alexander J Denner, Brenton Karl Ahrens, Corey N Fishman, Judith M Matthews, Michael W Dunne, Sailaja Puttagunta and Sofinnova Venture Partners Ix,.
View institutional ownership trends
.

How do I buy shares of Iterum Therapeutics?

Shares of ITRM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Iterum Therapeutics' stock price today?

One share of ITRM stock can currently be purchased for approximately $1.31.

How much money does Iterum Therapeutics make?

Iterum Therapeutics (NASDAQ:ITRM) has a market capitalization of $16.02 million and generates $40,000.00 in revenue each year. The company earns $-91,560,000.00 in net income (profit) each year or ($3.5794) on an earnings per share basis.

How can I contact Iterum Therapeutics?

Iterum Therapeutics' mailing address is BLOCK 2 FLOOR 3 HARCOURT CENTRE HARCOURT STREET, DUBLIN L2, 2. The official website for the company is www.iterumtx.com. The company can be reached via phone at (531) 903-8920 or via email at ir@iterumtx.com.

This page (NASDAQ:ITRM) was last updated on 12/6/2022 by MarketBeat.com Staff